S&P Futures
4,350.00 +24.50 (+0.57%) Dow Futures
33,880.00 +155.00 (+0.46%) Nasdaq Futures
14,981.75 +115.25 (+0.78%) Russell 2000 Futures
1,808.60 +10.00 (+0.56%) Crude Oil
91.12 +0.33 (+0.36%) Gold
1,856.60 -9.50 (-0.51%)
Rubius Therapeutics, Inc. (RUBY)
Chart Events
Performance Outlook
| Previous Close | 0.0162 |
| Open | 0.0162 |
| Bid | 0.0000 x 1200 |
| Ask | 0.0000 x 800 |
| Day's Range | 0.0162 - 0.0166 |
| 52 Week Range | 0.0032 - 0.4700 |
| Volume | |
| Avg. Volume | 76,700 |
| Market Cap | 1.466M |
| Beta (5Y Monthly) | 2.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9500 |
| Earnings Date | Nov 07, 2023 - Nov 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RUBY
Related Research
- Rubius Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 04/25/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
BenzingaRubius Therapeutics Outlines Dissolution Plan, After Unsuccessful Attempt On Alternatives
In November 2022, Rubius Therapeutics Inc (NASDAQ: RUBY) initiated a process to explore a range of strategic alternatives and planned to engage an investment bank to act as a strategic advisor. But the battered company failed to find any alternatives, and the company's board approved a plan of liquidation and dissolution. The biotech said its board approved the plan with a special meeting of Rubius' stockholders being lined up to seek a green light, per an SEC filing. The biotech terminated its
BenzingaRubius Therapeutics Cuts Almost 85% Of Its Workforce, Starts Looking For Strategic Alternatives
Rubius Therapeutics Inc (NASDAQ: RUBY) initiated a process to explore a range of strategic alternatives and plans to engage an investment bank to act as a strategic advisor for this process. In September, Rubius announced plans to restructure and align resources extending the company's cash runway until the end of 2023. As a result of this process, Rubius is reducing its workforce by 84% and will retain certain employees to execute the process. The company also appointed Dannielle Appelhans as p
GlobeNewswireRubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes
Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to ma
